Available Technologies

Browse Penn-owned technologies available for licensing.

Search Results - cell+therapy

10 Results Sort By:

Neuroprotection in TBI/Concussion via Dietary Supplement

A dietary supplement that protects brain cells from the effects of TBI and concussion Problem: Traumatic brain injury (TBI) is a major cause of death and disability. Mild TBIs (such as concussion) are particularly common for athletes and warfighters and can produce disabilities without immediate brain cell death. This may be due to damage to...

Published: 11/15/2021

Inventor(s):

Keywords(s):

Category(s):

Tumor suppression by retinoic acid pathway inhibition

­ Targeting retinoic acid (RA) synthesizing enzymes or RA receptors with small molecules boosts the immune system towards a tumor rejection response Problem: Hepatocellular carcinoma (HCC) is the most common liver cancer globally. In the US alone, 33 000 patients are diagnosed yearly, 27 000 of which will die. Once metastasized, HCC shows...

Published: 11/11/2021

Inventor(s):

Keywords(s):

Category(s):

Adoptive T cell therapy for cancer using Mutant KRAS-specific T cell receptors for T cell engineering

We have isolated, cloned, and characterized multiple T cell receptors (TCRs) from human donors specific for common mutations in KRAS and restricted to highly prevalent HLA types. These TCRs, protected by a Penn provisional filing, are suitable for T cell engineering for the adoptive immunotherapy of cancer patients of select HLA types and tumors expressing...

Published: 10/9/2021

Inventor(s):

Keywords(s):

Category(s):

Differentiation of induced pluripotent stem cells into retinal progenitor cells and mature, functional human retinal ganglion cells

Simplified and reproducible two-step differentiation method optimized for efficient differentiation of human-induced pluripotent stem cells into retinal progenitor cells and functional retinal ganglion cells Problem: More than three million Americans live with glaucoma – a disease that can cause blindness resulting from optic nerve damage....

Published: 10/4/2021

Inventor(s):

Keywords(s):

Category(s):

Efficient and controllable genome editing complex

A split enzyme complex enabling precise gene editing Technology Overview: The ability to target DNA deaminases to specific loci in concert with CRISPR/Cas systems has opened up new frontiers with the potential to transform biology and medicine by allowing for precise genome editing. At the same time, current DNA “base editors” typically...

Published: 6/2/2021

Inventor(s):

Keywords(s):

Category(s):

Gum-health promoting smart dental implant system

Dental implant that inhibits plaque accumulation and gingival tissue inflammation by photobiomodulation therapy delivered by embedded light-emitting diodes (LEDs) powered by electricity generated from the patient’s own oral motion. Problem: More than half of adults will lose one or more teeth in their lifetime. When a patient loses a tooth the...

Published: 2/9/2021

Inventor(s):

Keywords(s):

Category(s):

High performance CRISPR-Cas12a system for combinatorial genetic manipulation

CRISPR-Cas12a allowing for simultaneous editing of multiple genes in mammalian cells Problem: CRISPR-based gene editing technique has revolutionized the field of molecular biology. While CRISPR-Cas9-based methods are effectively used for single-gene knockout, multiplex gene editing remains a major challenge. Unlike Cas9, Cas12a can be used for multigene...

Published: 11/5/2020

Inventor(s):

Keywords(s):

Category(s):

Rapid and ultrasensitive profiling of EGFRvIII mutations in cancer and normal tissue

A method to rapidly detect the presence of EGFRvIII mutations in cancers and normal tissue using digital PCR. Problem: Glioblastoma multiforme (GBM) is a devastating brain cancer with poor prognosis. EGFRvIII is a mutation in the Extracellular Growth Factor Receptor that frequently occurs in GBM tumors. Targeting EGFRvIII mutations is an emerging...

Published: 10/5/2020

Inventor(s):

Keywords(s):

Category(s):

Design of canine antibodies for targeted therapeutics

Methods for generating single chain variable region Fragments (scFvs) for use as targeting agents for the treatment of infectious, inflammatory, and neoplastic diseases in dogs. Problem: Cancer is the leading cause of death in our current canine pet population. Previous studies have found that 45% of dogs aged 10 years or older and 23% of dogs...

Published: 3/11/2020

Inventor(s):

Keywords(s):

Category(s):

Fully human anti-mesothelin CAR with low immunogenicity for in vivo persistence of anti-tumor engineered T cells

The fully human CAR targets mesothelin, a surface protein overexpressed in several cancer types. P4, a human antibody fragment that binds human mesothelin with high specificity, is fused to T cell signaling domains such as 28z. The T cells engineered to express this CAR are shown to shrink tumors in a mouse model bearing human ovarian tumors overexpressing...

Published: 1/29/2020

Inventor(s):

Keywords(s):

Category(s):